BTIG keeps price targets on Oruka and Bicara Therapeutics unchanged
BTIG held its price target at $151 per share for Oruka Therapeutics and at $39 per share for Bicara Therapeutics, Dow Jones Newswires reported.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
BTIG reaffirmed its price targets for two biotech companies: $151 per share for Oruka Therapeutics (ORKA) and $39 per share for Bicara Therapeutics (BCAX). Dow Jones Newswires published the information on October 19, 2026, citing Benzinga ratings data.
Both reports cover only the maintenance of earlier targets, with no revision to the valuations.
why it matters
Keeping a price target in place means the analyst is not changing the valuation of the stock. For investors in small-cap biotech, notes like these usually serve as background information and do not by themselves change the picture for either company.
tags
instruments
sources
- Oruka Therapeutics Price Target Maintained With a $151.00/Share by BTIG — Dow Jones Newswires, 19 October 2026 at 10:04 UTC
- Bicara Therapeutics Price Target Maintained With a $39.00/Share by BTIG — Dow Jones Newswires, 19 October 2026 at 10:07 UTC
- Live Nation Price Target Maintained With a $215.00/Share by BTIG — Dow Jones Newswires, 19 October 2026 at 10:24 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗